David W. Scott

David W. Scott is an advisor at TeraImmune and a leading expert in the development of Disease-targeting Foxp3+ T regulatory T cells for personalized Treg therapy.

Scott began their career as a postdoctoral fellow at the National Institute of Allergy and Infectious Diseases (NIAID), where they worked from 2007 to 2011. David then took on the role of research assistant professor at MED, USUHS, from July 2015 to March 2018. In April 2018, they joined TeraImmune LLC as vice president of research, a position they held until August 2019.

Scott’s groundbreaking work has led to significant advancements in the field of personalized Treg therapy, and they continue to be a leading voice in the field today.

David W. Scott received their doctorate in biochemistry from Chungnam National University.